News
3h
Zacks.com on MSNCRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on ItCRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on ...
Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $42.5 and $55.0 for CRISPR Therapeutics, spanning the last three ...
CRISPR Therapeutics: 2025 TIME100 Most Influential CompaniesCRISPR Therapeutics is a biotech company that borrows its name from the groundbreaking gene editing technology CRISPR. As of last year ...
2don MSN
A Ph.D. student in biomolecular engineering at the University of California, Santa Cruz, has built a software program ...
6d
TipRanks on MSNCrispr Therapeutics AG Stock Soars Amid Clinical AdvancesCrispr Therapeutics AG ( ($CRSP) ) has risen by 7.26%. Read on to learn why. Crispr Therapeutics AG has seen a notable ...
CRISPR Therapeutics (NASDAQ:CRSP) operates within the biotechnology segment, which remains active across key indices like the ...
We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap’s Substack. In this article, we will ...
Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large markets. Click for my CRSP update.
With half a million people having already received multi-cancer early detection (MCED) screening, patients are and will continue to be asking about these blood tests during their visits, physicians ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results